Trump brings back the “most favored nation” initiative in a bid to lower drug prices in the U.S.
The Trump administration is reintroducing a contentious policy aimed at reducing U.S. pharmaceutical costs by aligning them with prices in other high-income countries, as detailed in an executive order issued